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Background: The exact mechanisms of morphine-induced dependence and withdrawal symptoms remain unclear.
In order to identify an agent that can prevent withdrawal syndrome, many studies have been performed. This study
was aimed to evaluate the effect of gap junction blockers; carbenoxolone (CBX) or mefloquine (MFQ); on morphine
withdrawal symptoms in male rat.
Adult male Wistar rats (225 – 275 g) were selected randomly and divided into 10 groups. All groups underwent
stereotaxic surgery and in order to induce dependency, morphine was administered subcutaneously) Sc) at an
interval of 12 hours for nine continuous days. On the ninth day of the experiment, animals received vehicle or CBX
(100, 400, 600 μg/10 μl/rat, icv) or MFQ (50, 100 and 200 μg/10 μl/rat, icv) after the last saline or morphine (Sc)
injection. Morphine withdrawal symptoms were precipitated by naloxone hydrochloride 10 min after the
treatments. The withdrawal signs including: jumping, rearing, genital grooming, abdomen writhing, wet dog shake
and stool weight, were recorded for 60 minutes.
Results: Results showed that CBX and MFQ decreased all withdrawal signs; and the analysis indicated that they
could attenuate the total withdrawal scores significantly.
Conclusion: Taking together it is concluded that gap junction blockers prevented naloxone-precipitated
withdrawal symptoms.
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It is well known that repeated administration of opiates
results in physical dependence. This major side effect of
opiates administration, limits their clinical application
[1]. Dependence is a behavioral state requiring continued
drug administration to avoid a series of aversive with-
drawal symptoms. Therefore, new drugs and strategies
are under investigation for preventing of opiate depend-
ence as well as withdrawal signs in a wide variety of ani-
mal species. The neurotransmitter systems have been
widely studied to find out the involved mechanisms of
withdrawal symptoms. Several lines of evidence indicate
the involvement of noradrenergic system in opiate* Correspondence: Kambizhassanzadeh@gmail.com
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reproduction in any medium, provided the orwithdrawal symptoms [2-4]. Although the factors and the
brain regions or nucleolus involved in opiate dependence
and withdrawal symptoms have been heavily investigated
during two past decades. However the exact mechanisms
of these phenomena are not completely understood.
The locus coeruleus (LC) area has been found to be the
most sensitive site for the elicitation of motor aspects of
opiate withdrawal [5,6]. It is a bilateral nucleus in the
brainstem consisting mostly of noradrenergic neurons.
Through a widespread efferent projection system, the locus
coeruleus–noradrenergic (LC-NE) system supplies norepin-
ephrine (NE) throughout the central nervous system [7].
During withdrawal of the opiates, the LC neurons exhibit an
augmented activation of their noradrenergic discharge activ-
ity. Also there is growing evidence that gap junctions play
an important role in the synchronization of neuronal oscilla-
tory activity that has been implicated in many cognitive
processes and in the generation of epileptic discharges [8].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tween the membranes of two abutting cells which allow
direct electrical communication between cells [8]. Inter-
cellular communication mediated by gap junction chan-
nels plays an important role in a variety of tissues,
including the nervous system, lens, and heart, by allowing
the passage of ions and small molecules between adjacent
cells [9]. To date, the most thoroughly studied problem
has been the involvement of gap junctions in seizure activ-
ity and the possibility of applying gap junction blockers to
decrease epileptic discharges [10].
From the other side, carbenoxolone (CBX), a well-known
gap junction inhibitor, could block the electrical coupling of
neurons in LC therefore decreased synchronization of the
spontaneous activity in this site [11].
CBX is a derivative of glycyrrhetinic acid, which has
been used in the treatment of gastric and duodenal ul-
cers [12], directly binds to and blocks a broad spectrum
of the connexins (Cx) that make up gap junctions or he-
michannels [13,14].
In addition CBX could block the voltage-gated Ca2+
channels [15] and NMDA-evoked currents [16]. Fur-
thermore, CBX is known to enhance the effects of
endogenous glucocorticoid hormones by inhibiting
11beta-hydroxysteroid dehydrogenase [17].
Mefloquine, another potent gap junction blocker has
been found to be relatively selective for certain subtypes of
gap junctions [18]. Mefloquine has been commonly used
in the prophylaxis and treatment of malaria and it could
inhibit the IP3- induced Ca
2+ release [19], inhibition of
acetylcholinesterase activity [20], blockade of adenosine
A2A receptors [21] and inhibition of ATP-sensitive K
channels [22].
Because of the similarity between withdrawal sings
and the firings occur during the seizure and the role of
gap junction inhibitors on preventing of epileptic dis-
charges, in the present study we were interested to verify
the effect of intracerebroventricular (icv) central admin-
istration of carbenoxolone and mefloquine as a gap junc-
tion blockers on morphine withdrawal symptoms.
Methods
Animals
Male Wistar rats (225-275 g) were purchased from the
Pasteur Institute of Iran. They were housed six rats per
cage (40 × 40 × 20 cm) at laboratory temperature (20 ±
3°C) and humidity (60%) under a 12-h light–dark cycle
(lights on at 07:00 A.M). Food (lab chow) and water were
available ad libitum. All procedures for animals were ap-
proved by the research committee of the Tabriz University
of Medical Sciences and were performed according to the
Guide for Care and Use of Laboratory Animals published
by the United States National Institutes of Health (NIH
Publication No. 85–23, revised 1985).Experimental groups
Rats were randomly divided into 10 groups:
1) One chronically subcutaneously (sc) normal saline
solution (1 mL/kg, sc) and normal saline solution
(10 μL/rat, icv) treated group (n = 8)
2) One chronically subcutaneously (sc) normal saline
solution (1 mL/kg, sc) and DMSO 25% in saline
(10 μL/rat, icv) treated group (n = 8)
3) One chronically subcutaneously (sc) Morphine and
normal saline solution (10 μL/rat, icv) treated group
(n = 8): Control for carbenoxolone
4) One chronically subcutaneously (sc) Morphine and
DMSO 25% in saline (10 μL/rat, icv) treated group
(n = 8): Control for mefloquine
5) Three chronically subcutaneously (sc) Morphine and
CBX (100, 400, 600 μg/10ul/rat, icv) treated groups
(n = 8)
6) Three chronically subcutaneously (sc) Morphine and
MFQ (50, 100 and 200 μg/10 μl/rat, icv) treated
groups (n = 8).
Surgery and icv cannula implantation
Rats were anesthetized with a mixture of ketamin
(100 mg/Kg, ip) and xylazine (5 mg/Kg, ip) and then
placed on a stereotaxic apparatus and secured using blunt
rodent ear bars. Lidocaine (2% V/V) was used for local
anesthesia then the skull was surgically exposed and a
stainless-steel guide cannula (3.4 mm long, 0.65 mm outer
diameter, 23 gauge needle) was unilaterally implanted in
to the injection site (coordinates for site of in injection:
−0.8 mm posterior, -1.3 mm midline to lateral and 3.4 mm
ventral according to the Rat Brain Atlas) [23]. The guide
cannula tips were placed 1 mm above the injection site to
minimize cellular damage. The guide cannula was fixed to
the skull using two stainless-steel screws anchored to the
skull and dental acrylic cement. Animals were allowed to
recover by about 7 days after surgery [24].
Drugs
The following drugs were used: Morphine sulfate and Nalox-
one naloxone hydrochloride (Darou Pakhsah Co. Iran),
carbenoxolone (Sigma-Aldrich, St. Louis, USA), mefloquine
(Sigma-Aldrich, St. Louis, USA), ketamin (Trittau, Germany)
and xylazine (Alfasan, Netherland). Morphine, carbenoxo-
lone and naloxone were dissolved in normal saline (0.9%)
and MFQ dissolve in 25% dimethyl sulfoxide (DMSO) in sa-
line before injection. Naloxone was injected to the all groups.
Intracerebroventricular drug administration
Intracerebroventricular (icv) injection of CBX, MFQ, Sa-
line and DMSO 25% were performed by removing the
stylet from guide cannula and lowering a stainless steel
injector cannula (14 mm, 30 gauge needle) that extended
Table 1 Weighing factor of different withdrawal signs
Behavior signs Weighing factor
Jumping 4
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jector cannula was connected to a 25-μl hamilton
microsyringe by a polyethylene −20 (PE-20) tubing and
10 μl of CBX, MFQ or their vehicles were infused over
60s period. In order to minimize the drug back flow into
the injection track, the cannula was gently withdrawn
60s after the injection and followed by replacement of
the stylet. During the filling of injection system, a small
air bubble was introduced into the PE-20 tubing to
monitor the movement of the fluid during the injection.
Induction of morphine dependence
In order to induce the dependency, additive doses of
morphine were administered subcutaneously for nine
days as follows: Day 1: 5 mg/kg /12 h, Day 2,3: 10 mg/
kg/12 h, Day 4,5: 15 mg/kg /12 h, Day 6,7: 20 mg/kg/
12 h, Day 8,9: 25 mg/kg/12 h. On the ninth day only the
morning dose of morphine was injected then CBX or
MFQ or their vehicles (saline or DMSO 25%, respect-
ively) administered after 20 minutes. The method for
additive doses of morphine was adapted from previous
studies [25,26] which indicated that the dependency was
established using this summing doses.
Induction of morphine withdrawal
In order to induce withdrawal symptoms, naloxone
(4 mg/kg, ip) was injected on the ninth day, 30 minutes
after the morning dose of morphine injection (10 minutes
after drugs or their vehicles injection). The chosen dose
for naloxone was based on previous studies [25].Figure 1 Naloxone (4 mg/kg)-induced TWS in morphine-dependent ra
mean ± S.E.M. ***p < 0.001 different from control (morphine-dependent DMMeasurement of behavioral signs
Immediately after naloxone injection, the behavioral assess-
ment of opioid withdrawal signs including jumping, rearing,
genital grooming, abdomen writhing and wet-dog-shake
was started for one hour. Animals were studied individually
in a clear plexiglass chamber (50 × 25 × 15 cm) that was
placed in other dark chamber to avoid environmental per-
turbations. A digital camera connected to a recording com-
puter was placed on the inner chamber to simultaneously
show the rats behaviors. The reactions of each animal were
evaluated by an observer who was not aware of the nature
of the treatment received by that animal. The behaviors of
all animals were evaluated by the same observer.
In present study the total withdrawal score was calcu-
lated for each animal in addition to reporting the symp-
toms alone because the individual withdrawal signs
under the various conditions appear different patterns of
activity and there were significant differences in the spe-
cific behaviors exhibited by individual animals. Thus, the
total withdrawal score measuring shows a general trend
in the composite withdrawal scores which might be dif-
fered under different conditions [27].
To do this, 5 assessed signs in an animal were scored on
the basis of the division of absolute frequency of each be-
havior into its respective weighting factor (Table 1). Then
the scores of withdrawal signs were added to obtain a total
withdrawal score (TWS) for each animal [24,27,28].
Locomotor activity test
Locomotor activity was assessed by direct observation
using interval scale that measures the frequency of cross-
ing the lines painted on the underside of floor of the Plexi-
glas behavioral arena by each animal. Locomotor activity
test was done before and after icv injection [29].
Histological verification of cannula placement
On completion of each experiment for evaluation the pre-
cise injecting site , methylene blue solution (5 μL/rat, icv)
was injected to the cannula, and then animals werets in comparison to saline treated animals. Data are expressed as
SO 25% microinjected group). M =Morphine, S = Saline.
Figure 2 Effects of icv injection of carbenoxolone (100, 400, 600 μg/rat) on the expression of naloxone (4 mg/kg)-induced withdrawal
signs in morphine-dependent rats. Data are expressed as mean ± S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001 different from control (morphine-
dependent DMSO 25% microinjected group). M =Morphine, S = Saline, CBX = carbenoxolone.
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The brain of each animal was dissected out and cut along
the coronal plane to verify the placement of the guide can-
nula and the distribution of the methylene blue in the ven-
tricles after the behavioral tests. Data for only those
animals that displayed a uniform distribution of methylene
blue in the ventricles were considered for statistical ana-
lysis. Overall, six animals were discarded because the
placement of the guide cannula was incorrect.
Data analysis
Statistical comparisons among the experimental groups
were made by a one way analysis of variance (ANOVA)Figure 3 Effects of icv injection of carbenoxolone (100, 400, 600 μg/r
morphine-dependent rats. Data are expressed as mean ± S.E.M. ***p < 0.0
microinjected group). M =Morphine, S = Saline, CBX = carbenoxolone.followed by Tukey’s post-hoc test for multiple comparisons.
All results are shown as the mean ± SEM (standard error of
the mean), with statistical significance set at p < 0.05.
Results and discussion
Naloxone-induced withdrawal
Animals received additive doses of morphine twice a day
for nine days. In order to induce withdrawal symptoms, na-
loxone (4 mg/kg, ip) was injected. The results in Figure 1
show that there was a significant (P < 0.001) difference in
the TWS between saline + saline or DMSO 25% and con-
trol groups (morphine + saline or DMSO 25%). Data ana-
lysis indicated that the withdrawal signs including: jumping,at) on the expression of naloxone (4 mg/kg)-induced TWS in
01 different from control (morphine-dependent DMSO 25%
Figure 4 Effects of icv injection of mefloquine (50, 100, 200 μg/rat) on the expression of naloxone (4 mg/kg)-induced withdrawal signs
in morphine-dependent rats. Data are expressed as mean ± S.E.M. *p < 0.05, **p < 0.01, ***p < 0.001 different from control (morphine-dependent
DMSO 25% microinjected group). M =Morphine, S = Saline, MFQ =Mefloquine.
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shake were significantly greater in the control groups which
received morphine compared to saline or DMSO 25%
treated animals which means that the animals in the con-
trol group has already became dependent.
Effect of icv administration of carbenoxolone on
morphine withdrawal signs
The results in Figure 2 revealed that icv injection of
CBX (600 μg/10ul/rat, icv) significantly decreased all
withdrawal signs except abdomen writhing [Figure 2]
(P < 0.001 for all signs). In addition we found that
carbenoxolone with all doses used in this study induced
a significant decrease in TWS in comparison with the
control group [Figure 3] (P < 0.001).
Effect of icv administration of mefloquine on morphine
withdrawal signs
Our findings in this study have shown that icv administra-
tion of mefloquine (50, 100 and 200 μg/10 μl/ rat)Figure 5 Effects of icv injection of mefloquine (50, 100, 200 μg/rat) o
morphine-dependent rats. Data are expressed as mean ± S.E.M. ***p < 0.0
microinjected group). M =Morphine, S = Saline, MFQ =Mefloquine.decreased all withdrawal signs significantly [Figure 4] (P <
0.001). In addition the results indicated that icv injection
of mefloquine resulted in a significant decrease in TWS
compared to the control group [Figure 5] (P < 0.001).
The results of this study showed that stereotaxic sur-
gery and icv injection of DMSO 25% had no effect
on naloxone-induced opioid withdrawal symptoms in
morphine-dependent rats while gap junction inhibitors
(CBX and MFQ) significantly decreased the withdrawal
signs. Locomotor activity test of rats with icv microin-
jected by CBX or MFQ was done to rule out the occur-
rence of motor performance hampering effect of drugs.
The data showed that icv injection of CBX or MFQ had
no significant effect on rats’motor performance. Thus, the
alleviative effect of CBX or MFQ on opioid withdrawal is
not ensued from suppression of motor activity.
Different drugs and strategies have been investigated
to find an effective approach for preventing opioid de-
pendence and withdrawal symptoms. Neurotransmitter
systems, especially noradrenergic pathway has beenn the expression of naloxone (4 mg/kg)-induced TWS in
01 different from control (morphine-dependent DMSO 25%
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http://www.jbiomedsci.com/content/20/1/77found to play a key role in appearance of withdrawal
symptoms. It has been reported that chronic morphine
treatment may lead to a reduction in expression of in-
hibitory opioid peptides. These processes with the con-
currently increase in the activity of glutamatergic
neurons may lead to the enhancement of activity of nor-
adrenergic system and somatic signs during drug de-
pendence and withdrawal [30].
Some brain nucleuses especially LC appears to mediate
somatic signs of opiate withdrawal. It has been reported
that acute opiates administration inhibit LC neurons and
subsequently inhibit cAMP This effect may lead to de-
crease in protein kinase A (PKA) activity and the phos-
phorylation rate of cAMP response element binding
protein (CREB). These selective effects of morphine on
cAMP protein phosphorylation indirectly generate spe-
cific behaviors commonly associated with addiction, tol-
erance and withdrawal [31,32]. Indeed if morphine
treatment persists and is then abruptly terminated, LC
neurons will increase the frequencies of action poten-
tials. Therefore, the symptoms of morphine withdrawal
will be produced [33,34].
Also it has been suggested that neuronal connections
outside the LC play an important role in the withdrawal-
induced activation of these nucleus [35].
The results of the present study for the first demon-
strate that central administration of gap junction blocker
such as carbenoxolone could alleviate opioid withdrawal
symptoms in morphine-dependent rats.
Previous studies reported that CBX directly binds to
and blocks a broad spectrum of the connexins that make
up gap junctions [13,14]. CBX microinjected bilaterally
into the substantia nigra (pars reticulata) also produced
a dose-dependent reduction in the duration and severity
of seizures [10].
CBX is a broad-spectrum gap junction blocker believed
to act on a range of connexins and pannexins, with add-
itional anti-inflammatory and mineralocorticoid- like
properties [36], and has been shown in vitro to reduce
seizure-like after discharges and spontaneous activity in
electrical stimulation [37,38].
Experimental and theoretical evidence suggests that
direct electrotonic communication between neurons via
gap junctions, in combination with synaptic and ionic
mechanisms, might contribute to the generation or
maintenance of seizures [39-41].
Furthermore in a previous study, it has been shown
that CBX might enhance the anticonvulsant action of
some antiepileptics, such as diazepam, gabapentin,
phenobarbital, felbamate and valproate [42], suggesting
its potential usefulness in the human therapy of some
types of pharmacoresistant epilepsies.
In another part of study we showed that MFQ as a po-
tent and selective Cx36 gap junction blocker [43] couldprevent opioid withdrawal signs and gathering the data
from different symptoms according to Rasmussen et al.
method, showed that mefloquine could attenuate the
total withdrawal scores which is depicted in Figure 5.
Cx36 expression is found in almost all brain areas, in-
cluding neocortex, brainstem, basal ganglia, hippocampus,
and cerebellum [44,45]. Also MFQ is find to acts as an in-
hibitor of P-glycoprotein [46] and, therefore, it can in-
crease the concentrations of other drugs in the brain [47].
In addition it has been shown that MFQ significantly
increased IPSCs frequency in brain slices isolated from
mouse [48] and this property might be helpful in attenu-
ating of firings during withdrawal sings exhibition.
Conclusion
Taking together we found that central administration of
gap junction blockers; carbenoxolone or mefloquine
prevented morphine-induced withdrawal symptom in rats.
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